Abstract
Various natural products, such as physostigmine, have long been recognized as inhibitors of the enzyme acetylcholinesterase. Since the recent approval of galanthamine for the treatment of Alzheimers disease by the blockage of acetylcholine degradation, attempts to find other inhibitors of the enzyme have multiplied, leading to promising candidates such as huperzine A. In this review, a listing is presented of natural product inhibitors, both alkaloid and nonalkaloid in origin. These have been isolated from plant, animal and microbial sources. Details of current testing methods on cholinesterases are given, including solution assays and screening techniques by TLC and HPLC.
Keywords: TLC Assays, HPLC Assay, Radiometric Method, AChE activity, Physostigmine, Huperzine A, Amaryllidaceae, Xanthone inhibitors
Current Organic Chemistry
Title: Natural Product Inhibitors of Acetylcholinesterase
Volume: 10 Issue: 8
Author(s): K. Hostettmann, A. Borloz, A. Urbain and A. Marston
Affiliation:
Keywords: TLC Assays, HPLC Assay, Radiometric Method, AChE activity, Physostigmine, Huperzine A, Amaryllidaceae, Xanthone inhibitors
Abstract: Various natural products, such as physostigmine, have long been recognized as inhibitors of the enzyme acetylcholinesterase. Since the recent approval of galanthamine for the treatment of Alzheimers disease by the blockage of acetylcholine degradation, attempts to find other inhibitors of the enzyme have multiplied, leading to promising candidates such as huperzine A. In this review, a listing is presented of natural product inhibitors, both alkaloid and nonalkaloid in origin. These have been isolated from plant, animal and microbial sources. Details of current testing methods on cholinesterases are given, including solution assays and screening techniques by TLC and HPLC.
Export Options
About this article
Cite this article as:
Hostettmann K., Borloz A., Urbain A. and Marston A., Natural Product Inhibitors of Acetylcholinesterase, Current Organic Chemistry 2006; 10 (8) . https://dx.doi.org/10.2174/138527206776894410
DOI https://dx.doi.org/10.2174/138527206776894410 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
KMC, Concepts, Definitions and Praxis: What Elements are Applicable in What Settings in Which Local Circumstances?
Current Women`s Health Reviews Placebo Effects in Therapeutic Outcomes
Current Clinical Pharmacology Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Glucocorticoids, the Etiology of Obesity and the Metabolic Syndrome
Current Alzheimer Research HspB8 is Neuroprotective during Oxygen Glucose Deprivation and Reperfusion
Current Neurovascular Research Effect of Antioxidants on Heavy Metals Induced Conformational Alteration of Cytochrome C and Myoglobin
Protein & Peptide Letters Molecular Therapeutic Targets in Inflammation: Cyclooxygenase and NF-κB
Current Drug Targets - Inflammation & Allergy Pathogenesis of Major Depression by Stress Induced Hyperactivity of Hypothalmic-pituitary Adrenal Axis Mediated by Dysregulations of Neurotransmitter, Innate Immune Systems and Altered Brain micro RNA Expressions
Current Psychiatry Reviews Substrate Specificity of Rat DESC4, a Type II Transmembrane Serine Protease
Protein & Peptide Letters Effects of Ranolazine on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Meet Our Editorial Board Member:
Medicinal Chemistry Structure-Activity Studies on Alpha-Conotoxins
Current Pharmaceutical Design Pharmacotherapy of Down’s Syndrome: When and Which?
CNS & Neurological Disorders - Drug Targets Induction of RhoGAP and Pathological Changes Characteristic of Alzheimers Disease by UAHFEMF Discharge in Rat Brain
Current Alzheimer Research Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry The Risk That DSM-5 Will Give Personality Dimensions A Bad Name
Current Psychiatry Reviews Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Synthesis, Characterization and Antibacterial Evaluation of some New 1,2,4-triazolo[3,4-b][1,3,4]thiadiazines as Potential Antibacterial Agents
Letters in Drug Design & Discovery Role of Mitochondrial Protein Quality Control in Oxidative Stress-induced Neurodegenerative Diseases
Current Alzheimer Research Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy